secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2026-06-03T21:14:06+00:00
Accession:  0001104659-26-070173
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 3.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma raises $1.86M via warrant exercise inducement, issues new warrants for 20.7M shares
--------------------------------------------------------------------------------

- Gross proceeds of ~$1.86M from exercise of 10.344M existing warrants at reduced exercise price of $0.18 per share.
- Issued new unregistered warrants to purchase up to 20.688M common shares at $0.18, exercisable only after stockholder approval.
- New warrants expire five years from stockholder approval date; resale registration to be filed within 20 days.
- Maxim Group LLC acted as financial advisor, receiving 8% cash fee on gross proceeds.
- Net proceeds from the exercise will be used for working capital and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926070173/0001104659-26-070173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926070173/tm2616851d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-070173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer